Ingredient intelligence report
Ingredient hub · not a branded product review
Verdict
Safety, interactions, or risk profiles deserve extra scrutiny; involve a clinician before experimenting.
Last updated: 28 de marzo de 2026
Overall
Trust score summarizes evidence, safety, and hype gap in our fixed rubric - not a personal recommendation.
Best for
Six editorial checks applied to every published hub. Status reflects our fixed scoring bands, not a product lab test.
Human data exist but are uneven, narrow, or contested for the loudest claims.
Dosage discussion is documented on this hub; compare any bottle to studied ranges yourself.
Some gap between marketing certainty and trial endpoints remains visible.
This page is an ingredient hub (not a SKU review). Transparency is judged at the evidence-and-claim level, not for a single brand label.
Evidence is partial, industry-skewed, or not yet convincing at scale.
Notable interaction, population, or tolerability considerations deserve clinician review.
Formula
This hub treats Kava as a single compound for analysis. Evidence strength reflects human trial and review signal - not brand formulation claims or proprietary blends unless separately documented.
Kava
Listed dose (hub)
See dosage notes (varies by product)
Some human data exist, but trials are small, heterogeneous, or not aligned with popular claims.
Why it matters
Retail products vary by salt form, dose, and purity. The hub anchors what the compound can claim in evidence - not every bottle on the shelf.
Credibility
Editorial read of marketing narratives versus trial support and safety context. Not a regulatory finding.
Typical storefront and social narratives versus what human data actually test.
Elevated caution: prioritize safety and clinician input before benefit shopping.
Economics
Ingredient hubs are not pegged to a single SKU or live price feed. The read below ties value posture to evidence and hype - not checkout data.
Strained value context
Value is secondary to risk
When safety and interaction concerns dominate, price comparisons are misleading without clinician oversight.
Higher overall score with equal or lower hype gap in our model - navigation hints, not medical advice or guaranteed substitutes.
Some links elsewhere on the site may earn a commission. Rankings and scores are not influenced by affiliate relationships.
Stronger composite score with contained hype versus Kava in this dataset.
Stronger composite score with contained hype versus Kava in this dataset.
Stronger composite score with contained hype versus Kava in this dataset.
Short answers for search intent. The analysis sections above carry the full nuance.
Literature
Study quality varies by dose, endpoint, and population; use our evidence axis as a guide.
Safety
Side effects and interactions depend on medications and conditions; involve clinicians for pregnancy, bleeding risk, and polypharmacy.
Use labeled directions unless a clinician tailors dosing; stop and seek care for allergic reactions.
Product-level dosing varies. This section is general context, not a prescription.
Shorter pages tuned to how people ask - each links back here for the full file.
A few hand-picked entry points around Kava: categories, answers to narrow questions, and comparisons.
Grouped near Kava in the model - not interchangeable.
A common shortfall nutrient with roles in muscle and nerve function; certain forms help constipation; sleep claims are softer.
A chronobiotic hormone useful for circadian issues and some sleep onset problems; not a sedative for everyone.
Occasional constipation; Detox teas (problematic chronic use). Typical label framing: OTC protocols short term; chronic misuse harmful.
Swaps discussed alongside Kava - judge each on its own evidence.
No sponsored reviews
Editorial model. No paid verdicts.
Evidence-based analysis
Human trial signal, not storefront copy.
Continuously updated
Hubs revised as synthesis changes.
Scores compress ingredient evidence, dosage discussion, claim stress-testing, and hype gap. Outbound retailer links do not change the model output.
· ·